The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 5, 2004, Pages 455-463

  Schneck, Dennis W ^a   Birmingham, Bruce K ^b   Zalikowski, Julie A ^b   Mitchell, Patrick D ^b   Wang, Yi ^b   Martin, Paul D ^b   Lasseter, Kenneth C ^b   Brown, Colin D A ^b   Windass, Amy S ^b   Raza, Ali ^b  

^a ASTRAZENECA   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GEMFIBROZIL; LACTONE; METHYL GROUP; ORGANIC ANION TRANSPORTER; PLACEBO; ROSUVASTATIN;

ADULT; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG UPTAKE; HEALTH STATUS; HUMAN; IN VITRO STUDY; ISOTOPE LABELING; NONHUMAN; NORMAL HUMAN; OOCYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME; VOLUNTEER; XENOPUS;

ADMINISTRATION, ORAL; ADULT; ANIMALS; ANTILIPEMIC AGENTS; AREA UNDER CURVE; CELL LINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; FLUOROBENZENES; GEMFIBROZIL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; OOCYTES; ORGANIC ANION TRANSPORTERS; PYRIMIDINES; REFERENCE VALUES; SULFONAMIDES; XENOPUS;

EID: 11144354934     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2003.12.014     Document Type: Article

References (32)

1. Shek A., Ferrill M.J. Statin-fibrate combination therapy. Ann Pharmacother. 35:2001;908-917
2. Murdock D.K., Murdock A.K., Murdock R.W., Olson K.J., Frane A.M., Kersten M.E., et al. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J. 138:1999;151-155
3. Taj A., Rajeshawari M., Isley W. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. South Med J. 90:1997;546-547
4. van Puijenbroek E.P., Du Buf-Vereijken P.W., Spooren P.F., van Doormaal J.J. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med. 240:1996;403-404
5. Pierce L.R., Wysowski D.K., Gross T.P. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 264:1990;71-75
6. Pogson G.W., Kindred L.H., Carper B.G. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am J Cardiol. 83:1999;1146
7. Farmer J.A. Learning from the cerivastatin experience. Lancet. 358:2001;1383-1385
8. Staffa J.A., Chang J., Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 346:2002;539-540
9. Kyrklund C., Backman J.T., Neuvonen M., Neuvonen P.J. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther. 73:2003;538-544
10. Backman J.T., Kyrklund C., Kivistö K.T., Wang J.-S., Neuvonen P.J. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther. 68:2000;122-129
11. Kyrklund C., Backman J.T., Kivistö K.T., Neuvonen M., Laitila J., Neuvonen P.J. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther. 69:2001;340-345
12. Backman J.T., Kyrklund C., Neuvonen M., Neuvonen P.J. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther. 72:2002;685-691
13. Prueksaritanont T., Zhao J.J., Ma B., Roadcap B.A., Tang C., Qiu Y., et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther. 301:2002;1042-1051
14. Olsson A.G., McTaggart F., Raza A. Rosuvastatin a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 20:2002;303-308
15. Olsson A.G., Istad H., Luurila O., Ose L., Stender S., Tuomilehto J., et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J. 144:2002;1044-1051
16. Brown W.V., Bays H.E., Hassman D.R., McKenney J., Chitra R., Hutchinson M., et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia a randomized, double-blind, 52-week trial. Am Heart J. 144:2002;1036-1043
17. McCormick A.D., McKillop D., Butters C.J., Miles G.S., Baba T., Touchi A., et al. ZD4522 - an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions metabolic studies in human in vitro systems. [abstract] J Clin Pharmacol. 40:2000;1055
18. Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, et al. Metabolism, excretion and pharmacokinetics of rosuvastatin. Clin Ther 2003;25:2822-35
19. Hsiang B., Zhu Y., Wang Z., Wu Y., Sasseville V., Yang W.P., et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 274:1999;37161-37168
20. Nakai D., Nakagomi R., Furuta Y., Tokui T., Abe T., Ikeda T., et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther. 297:2001;861-867
21. Shitara Y., Itoh T., Sato H., Li A.P., Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther. 304:2003;610-616
22. Brown C.D.A., Windass A., Bleasby K., Lauffart B. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C. [abstract] Atheroscler Suppl. 2:2001;90
23. Tucker G.T., Houston J.B., Huang S.-M. Optimizing drug development strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Clin Pharmacol Ther. 70:2001;103-114
24. Spence J.D., Munzo C.E., Hendricks L., Latchinian L., Khouri H.E. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol. 76:1995;80A-83A
25. Yamazaki M., Akiyama S., Ni'inuma K., Nishigaki R., Sugiyama Y. Biliary excretion of pravastatin in rats contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter (cMoat). Drug Metab Dispos. 25:1997;1123-1129
26. Vormfelde S.V. Safety of statins (hydroxymethyl glutaryl coenzyme A reductase inhibitors) different mechanisms of metabolism and drug transport may have clinical relevance. Arch Intern Med. 161:2001;1012-1013
27. Prueksaritanont T., Subramanian R., Fang X., Ma B., Qiu Y., Lin J.H., et al. Glucuronidation of statins in animals and humans a novel mechanism of statin lactonization. Drug Metab Dispos. 30:2002;505-512
28. Prueksaritanont T., Tang C., Qiu Y., Mu L., Subramanian R., Lin J.H. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos. 30:2002;1280-1287
29. Martin P.D., Dane A.L., Schneck D.W., Warwick M.J. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther. 25:2003;459-471
30. Wang J.S., Neuvonen M., Wen X., Backman J.T., Neuvonen P.J. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos. 30:2002;1352-1356
31. Wen X., Wang J.-S., Backman J.T., Kivistö K.T., Neuvonen P.T. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos. 29:2001;1359-1361
32. Cooper K.J., Martin P.D., Dane A.L., Warwick M.J., Schneck D.W., Cantarini M.V. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol. 58:2002;527-531